BioPorto

Regulatory Filings • Jan 11, 2016

BioPorto has entered into a distribution agreement with Siemens Healthcare,
under which BioPorto will deliver an NGAL test adapted for Siemens Healthcare’s
BN II and BN ProSpec Systems. The agreement is exclusive with regard to those
instruments and has a worldwide scope. Siemens Healthcare’s BN Systems are
controlled systems that are designed for validated applications. Subsequent to
completion of the adaption of the NGAL test to those instruments, the agreement
includes a period in which Siemens Healthcare and BioPorto will collaborate to
bring the adapted test to market. Commercial sales will commence after
completion of the adaption. The agreement has significant strategic importance
to the availability of NGAL tests and the awareness of NGAL as a diagnostic
marker. BioPorto expects to see an economic effect of this agreement in the
second half of 2016.

Peter Mørch Eriksen, CEO of BioPorto, comments: "I am very pleased with the
distribution agreement and the cooperation with Siemens on getting NGAL adapted
for two of their systems and marketed. I expect this agreement to have minor
economic impact for BioPorto this year, because the test is only marketed in
the second half of 2016. In contrast, and especially since we are well underway
with building the NGAL market, the strategic importance is very significant as
could the economic impact become over time. "

For further information, please contact:

Peter Mørch Eriksen, CEO

Christina Thomsen, Investor Relations Manager

Telephone +45 4529 0000, e-mail investor@bioporto.com

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide,
of whom about 4 million die. Nevertheless, there has been no real progress in
methods of diagnosing kidney injury over the last half century. Existing
methods, such as serum creatinine determination, only signal kidney failure
24-72 hours after the injury has taken place. In contrast, NGAL rises to
diagnostic levels within a few hours of kidney injury and thus enables the
physician to make vital clinical decisions before the damage progresses to
potentially fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will contribute to
reducing hospital costs in the management of kidney injury and its
consequences.

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ Copenhagen stock exchange.